Vistagen Therapeutics, Inc. cotiza a 0.23 USD y tiene una capitalización bursátil de $10M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the t…
| Periodo | 2026-11 | 2026-08 | 2026-06 | 2026-02 |
|---|---|---|---|---|
| Real | — | — | $-0.37 | $-0.45 |
| Estimado | $-0.37 | $-0.36 | $-0.27 | $-0.48 |
| Sorpresa | — | — | -37.0% | +6.2% |
| Métrica | VTGN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -5683.7% | -38.6% | -5645.1% |
| Net Margin | -5491.3% | -33.6% | -5457.8% |
| FCF Margin | — | -13.9% | — |
| ROE | -196.2% | -40.4% | -155.8% |
| ROA | -143.5% | -32.0% | -111.5% |
| Current Ratio | 3.67 | 2.84 | +0.83 |
| Debt / Equity | — | 0.28 | — |